Program Leaders The Center organizes its cancer research into nine established scientific research programs that span the basic, clinical, translational, and population sciences: Cancer Cell Biology. Immunology, Molecular Therapeutics. Virology. Cancer Genetics, Clinical Research, Breast Cancer, Cancer Prevention and Control, and Cancer Epidemiology. Each program is led by outstanding researchers. With one exception, each program has 0.10 FTE devoted to its leadership. The exception is Clinical Research, the Center's largest program, which has 0.15 FTE. Five programs have single leaders;four have Program Co-Leaders. Program Leader responsibilities include: advising the Director on the Center's continued scientific and intellectual development and strategic planning;developing and promoting individual and collaborative research projects, advising and mentoring program members;organizing retreats, meetings. interest groups, and seminars;promoting interactions and collaboration both inside and outside the program;and advising the Director on Center operation. To meet these responsibilities. Program Leaders interact both formally (program meetings. retreats, etc) and informally with each other, program members, and other Center members. Program Leaders also interact both formally and informally with Senior Leaders. Formal interactions include the Program Planning Committee, retreats, core facility reviews, and individual/small group meetings with the Director. Informal interactions include individual meetings, faculty meetings, seminars, symposia, and committee meetings. Program Leaders meet with the Scientific Advisory Board and ad hoc consultants.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-37
Application #
8392151
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
37
Fiscal Year
2013
Total Cost
$255,532
Indirect Cost
$72,665
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Lim, Joseph K; Liapakis, Ann Marie; Shiffman, Mitchell L et al. (2018) Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Clin Gastroenterol Hepatol 16:1811-1819.e4
Wang, Gary P; Terrault, Norah; Reeves, Jacqueline D et al. (2018) Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. Sci Rep 8:3199
Phillips, Bonnie; Van Rompay, Koen K A; Rodriguez-Nieves, Jennifer et al. (2018) Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. J Virol 92:
Lianga, Noel; Doré, Carole; Kennedy, Erin K et al. (2018) Cdk1 phosphorylation of Esp1/Separase functions with PP2A and Slk19 to regulate pericentric Cohesin and anaphase onset. PLoS Genet 14:e1007029
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M et al. (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20:12
Dhungel, Bal Mukunda; Montgomery, Nathan D; Painschab, Matthew S et al. (2018) 'Discovering' primary effusion lymphoma in Malawi. AIDS 32:2264-2266
Cameron, Jennifer E; Rositch, Anne F; Vielot, Nadja A et al. (2018) Epstein-Barr Virus, High-Risk Human Papillomavirus and Abnormal Cervical Cytology in a Prospective Cohort of African Female Sex Workers. Sex Transm Dis 45:666-672
Stanley, Christopher C; van der Gronde, Toon; Westmoreland, Kate D et al. (2018) Risk factors and reasons for treatment abandonment among children with lymphoma in Malawi. Support Care Cancer 26:967-973
Dronamraju, Raghuvar; Jha, Deepak Kumar; Eser, Umut et al. (2018) Set2 methyltransferase facilitates cell cycle progression by maintaining transcriptional fidelity. Nucleic Acids Res 46:1331-1344
Koehler, Jennifer W; Miller, Andrew D; Miller, C Ryan et al. (2018) A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human Glioma. J Neuropathol Exp Neurol 77:1039-1054

Showing the most recent 10 out of 1525 publications